Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Implant
01
Overview
Carmustine is a small molecule chemotherapy drug classified as a nitrosourea alkylating agent. It is primarily used to treat various malignancies, including brain tumors (such as glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors), multiple myeloma (in combination with prednisone), Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Carmustine works by forming interstrand crosslinks in DNA and RNA through alkylation and carbamoylation of proteins such as glutathione reductase. This disrupts DNA replication and transcription processes in cancer cells, leading to cell death. Carmustine can be administered intravenously or as an implantable wafer (Gliadel) during surgery for certain brain tumors[1][2][3][4][5][6].
- Brand names
- BiCNUGliadel
- Other names
- β-chloro-nitrosourea1,3-bis(2-chloroethyl)-1-nitrosourea
02
Targets
DNAGSR (Glutathione reductase)
Beyond the preview
Go deeper on carmustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine.